Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correlation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1-positive individuals.
Chalouni M, Rodriguez-Centeno J, Samri A, Blanco J, Stella-Ascariz N, Wallet C, Knobel H, Zucman D, Alejos Ferreras B, Autran B, Thiebaut R, Raffi F, Arribas JR; NEAT 001/ANRS 143 Trial Study Group. Chalouni M, et al. Among authors: knobel h. PLoS One. 2020 Apr 8;15(4):e0230772. doi: 10.1371/journal.pone.0230772. eCollection 2020. PLoS One. 2020. PMID: 32267847 Free PMC article.
[Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study)].
Viciana P, Rubio R, Ribera E, Knobel H, Iribarren JA, Arribas JR, Pérez-Molina JA; Investigadores del Estudio CUVA. Viciana P, et al. Among authors: knobel h. Enferm Infecc Microbiol Clin. 2008 Mar;26(3):127-34. doi: 10.1157/13116748. Enferm Infecc Microbiol Clin. 2008. PMID: 18358210 Spanish.
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.
Arribas JR, Delgado R, Arranz A, Muñoz R, Portilla J, Pasquau J, Pérez-Elias MJ, Iribarren JA, Rubio R, Ocampo A, Sánchez-Conde M, Knobel H, Arazo P, Sanz J, López-Aldeguer J, Montes ML, Pulido F; OK04 Study Group. Arribas JR, et al. Among authors: knobel h. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):147-52. doi: 10.1097/QAI.0b013e3181a56de5. J Acquir Immune Defic Syndr. 2009. PMID: 19349870 Clinical Trial.
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].
Blasco AJ, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, López JC, Llibre JM, Lozano F, Miró JM, Podzamczer D, Santamaría JM, Tuset M, Zamora L, Lázaro P, Gatell JM; en representación de GESIDA. Blasco AJ, et al. Among authors: knobel h. Enferm Infecc Microbiol Clin. 2012 Jun;30(6):283-93. doi: 10.1016/j.eimc.2012.02.016. Epub 2012 Apr 22. Enferm Infecc Microbiol Clin. 2012. PMID: 22525829 Spanish.
[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013].
Blasco AJ, Llibre JM, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, López JC, Lozano F, Miró JM, Podzamczer D, Santamaría JM, Tuset M, Zamora L, Lázaro P, Gatell JM; en representación de GESIDA. Blasco AJ, et al. Among authors: knobel h. Enferm Infecc Microbiol Clin. 2013 Nov;31(9):568-78. doi: 10.1016/j.eimc.2013.06.002. Epub 2013 Aug 20. Enferm Infecc Microbiol Clin. 2013. PMID: 23969276 Spanish.
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group. Raffi F, et al. Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4. Lancet. 2014. PMID: 25103176 Clinical Trial.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabié A, Weiss L, Gatell JM; OLE/RIS-EST13 Study Group. Arribas JR, et al. Among authors: knobel h. Lancet Infect Dis. 2015 Jul;15(7):785-92. doi: 10.1016/S1473-3099(15)00096-1. Epub 2015 Jun 7. Lancet Infect Dis. 2015. PMID: 26062880 Clinical Trial.
Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
Berenguer J, Rivero A, Blasco AJ, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, Lázaro P, López JC, Llibre JM, Lozano F, Miró JM, Podzamczer D, Tuset M, Gatell JM; GeSIDA Antiretroviral Therapy Cost-efficacy Study Group. Berenguer J, et al. Among authors: knobel h. Enferm Infecc Microbiol Clin. 2016 Jun-Jul;34(6):361-71. doi: 10.1016/j.eimc.2015.07.012. Epub 2015 Aug 28. Enferm Infecc Microbiol Clin. 2016. PMID: 26321131
340 results